Quarterly report pursuant to Section 13 or 15(d)

NATURE OF BUSINESS AND ORGANIZATION (Details)

v3.24.3
NATURE OF BUSINESS AND ORGANIZATION (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Sep. 30, 2024
USD ($)
segment
Sep. 30, 2023
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Accumulated deficit   $ 244,987,090           $ 244,987,090     $ 202,761,017
Net loss   (14,664,719) $ (919,371) $ (26,641,983) $ (17,520,378) $ (10,178,640) $ (7,190,470) (42,226,073) $ (34,889,488)    
Unrestricted cash and cash equivalents   34,263,371           $ 34,263,371     9,564,988
Number of Reportable Segments | segment               1      
Fixed asset impairment charges               $ 0 0    
Uninsured cash balances   33,814,000           $ 33,814,000     $ 9,123,000
Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]               Costs and Expenses      
Subsequent event                      
Unrestricted cash and cash equivalents                   $ 28,600,000  
Cancer treatment research award through the National Cancer Institute (NCI)                      
Government Assistance Amount Cumulative   $ 2,000,000.0           $ 2,000,000.0      
Government Assistance Transaction Duration               3 years      
Grant received $ 1,980,000                    
Reduction in research and development               $ 602,000 $ 1,314,000    
Leasehold improvements                      
Property and equipment useful lives   64 months           64 months      
Minimum                      
Property and equipment useful lives   3 years           3 years      
Share-based compensation expiration period   12 months           12 months      
Maximum                      
Property and equipment useful lives   10 years           10 years      
Share-based compensation expiration period   3 years           3 years